HDAC9 and neoplasm: Although the majority of the drugs (48/60, or 74%) were not active in any scenario (Figure 3B,C), eight drugs were active in both the primary tumor (K29P-PC) and recurrent tumor (K29R-PC) primary cultures (PC): Three HDAC inhibitors (Panobinostat, SAHA, and Eninostat), two cyclin-dependent kinase inhibitors (Dinaciclib and BMS-387032), and inhibitors of PI3K/mTOR (BEZ 235), heat shock protein 90 (AUY922), and proteasome (Cafilzomib) (Figure 3C and Figure 4).